Research Papers:

Evolutionary selected Tibetan variants of HIF pathway and risk of lung cancer

Lucie Lanikova _, N. Scott Reading, Hao Hu, Tsewang Tashi, Tatiana Burjanivova, Anna Shestakova, Bhola Siwakoti, Binay Kumar Thakur, Chin Bahadur Pun, Amir Sapkota, Sarah Abdelaziz, Bing-Jian Feng, Chad D. Huff, Mia Hashibe and Josef T. Prchal

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:11739-11747. https://doi.org/10.18632/oncotarget.14340

Metrics: PDF 2267 views  |   HTML 2583 views  |   ?  


Lucie Lanikova1,2,*, N. Scott Reading1,3,4,*, Hao Hu5, Tsewang Tashi1, Tatiana Burjanivova6, Anna Shestakova1,4, Bhola Siwakoti7, Binay Kumar Thakur7, Chin Bahadur Pun7, Amir Sapkota8, Sarah Abdelaziz9, Bing-Jian Feng10, Chad D. Huff5, Mia Hashibe9, Josef T. Prchal1,11

1Division of Hematology, University of Utah School of Medicine, Salt Lake City, Utah, USA

2Institute of Molecular Genetics, Academy of Sciences, Prague, Czech Republic

3Institute for Clinical and Experimental Pathology, ARUP Laboratories, Salt Lake City, Utah, USA

4Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA

5University of Texas, MD Anderson Cancer Center, Houston, Texas, USA

6Department of Molecular Biology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin, Slovak Republic

7B.P. Koirala Memorial Cancer Hospital, Bharatpur, Chitwan, Nepal

8Maryland Institute for Applied Environmental Health, and University of Maryland College Park School of Public Health, Maryland, USA

9Division of Public Health, Department of Family & Preventive Medicine and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA

10Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah, USA

11Department of Pathophysiology and 1st Department of Medicine, 1st Faculty of Medicine, Charles University in Prague, Czech Republic

*These authors have contributed equally to this work

Correspondence to:

Josef T. Prchal, email: [email protected]

Mia Hashibe, email: [email protected]

Keywords: hypoxia, ENGL1/PHD2, EPAS1/HIF-2α, high-altitude adaptation, lung cancer

Received: June 15, 2016    Accepted: December 16, 2016    Published: December 28, 2016


Tibetans existed in high altitude for ~25 thousand years and have evolutionary selected unique haplotypes assumed to be beneficial to hypoxic adaptation. EGLN1/PHD2 and EPAS1/HIF-2α, both crucial components of hypoxia sensing, are the two best-established loci contributing to high altitude adaptation. The co-adapted Tibetan-specific haplotype encoding for PHD2:p.[D4E/C127S] promotes increased HIF degradation under hypoxic conditions. The Tibetan-specific 200 kb EPAS1 haplotype introgressed from an archaic human population related to Denisovans which underwent evolutionary decay; however, the functional variant(s) responsible for high-altitude adaptation at EPAS1/HIF-2α have not yet been identified. Since HIF modulates the behavior of cancer cells, we hypothesized that these Tibetan selected genomic variants may modify cancer risk predisposition. Here, we ascertained the frequencies of EGLN1D4E/C127S and EGLN1C127S variants and ten EPAS1/HIF-2α variants in lung cancer patients and controls in Nepal, whose population consists of people with Indo-Aryan origin and Tibetan-related Mongoloid origin. We observed a significant association between the selected Tibetan EGLN1/PHD2 haplotype and lung cancer (p=0.0012 for D4E, p=0.0002 for C127S), corresponding to a two-fold increase in lung cancer risk. We also observed a two-fold or greater increased risk for two of the ten EPAS1/HIF-2α variants, although the association was not significant after correcting for multiple comparisons (p=0.12). Although these data cannot address the role of these genetic variants on lung cancer initiation or progression, we conclude that some selected Tibetan variants are strongly associated with a modified risk of lung cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14340